InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
-0.34%
)
US TECH 100
16,902.00
(
-0.48%
)
Dow Jones
37,903.29
(
0.23%
)
Brent Oil
83.51
(
-2.78%
)
Bitcoin
57,557.57
(
-5.02%
)
Post# of 251668
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

AlpineBV_Miller

Send PM Follow Ignore
Followers 56
Posts 1150
Boards Moderated 0
Alias Born 11/12/2005

AlpineBV_Miller

Re: biomaven0 post# 132794

Saturday, 12/10/2011 3:55:56 PM

Saturday, December 10, 2011 3:55:56 PM

Post# of 251668


Well unless they believe the 100% cure was one of their drug arms, in which case they may secretly harbor hopes of showing superiority over daptomycin in this trial.



That wouldn't be harmed by an interim alpha spend. Nobody cares in this P2a if the alpha isn't perfectly holding to strict biostatistical rules. They could have done an interim and shown that as p=0.05, called it stat sig, and nobody (not even the FDA) would have squawked.

I just don't get it.

Unless otherwise indicated, this is the personal viewpoint of David
Miller and not necessarily that of Biotech Stock Research, LLC.
We're on Twitter at BiotechStockRsr

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up